Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2005
12/01/2005US20050265994 Using monclonal antibody for treatment and prevention of discomfort associated with cell proliferative disorders
12/01/2005US20050265993 Methods of treating autoimmune and inflammatory diseases
12/01/2005US20050265992 cell adhesion molecule determined to effect platelet aggregation, secretion, platelet spreading and cellular adhesion; thrombosis, atherosclerosis, heart attacks, stroke and other clinical disorders involving thrombus formation
12/01/2005US20050265991 For controlled release of compounds through the use of a chemically sensitive cantilever
12/01/2005US20050265987 Sulfatases and methods of use thereof
12/01/2005US20050265974 Recombinant viral-based malaria vaccines
12/01/2005US20050265971 Agent for treatment of breast cancer and pancreatic cancer comprising herpes simplex virus mutant
12/01/2005US20050265966 Methods of treating cancer using IL-21 and monoclonal antibody therapy
12/01/2005US20050265965 Modified cytokines for use in cancer therapy
12/01/2005US20050265963 Immunodynamic complexes and methods for using and preparing such complexes
12/01/2005US20050265961 Biodegradable poly(beta-amino esters) and uses thereof
12/01/2005US20050265937 Systems and methods for changing eye color appearance
12/01/2005US20050265928 Pulmonary malarial vaccine
12/01/2005US20050265924 Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
12/01/2005US20050265921 Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
12/01/2005DE102004023187A1 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie Identifying surface-associated antigens for tumor diagnosis and therapy
12/01/2005CA2776682A1 Tiacumicin b compound
12/01/2005CA2607686A1 Use of gelsolin to treat infections
12/01/2005CA2569094A1 Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
12/01/2005CA2567486A1 Measuring degree of polymerisation for capsular saccharides that contain sialic acid
12/01/2005CA2566903A1 Modified antigen-presenting cells
12/01/2005CA2566858A1 Process for the production of an influenza vaccine
12/01/2005CA2566745A1 Methods of treating cancer using il-21 and monoclonal antibody therapy
12/01/2005CA2566725A1 Truncated hepatitis c virus ns5 domain and fusion proteins comprising same
12/01/2005CA2566079A1 Nucleic acid microspheres, production and delivery thereof
12/01/2005CA2566075A1 Microspheres comprising protein and showing injectability at high concentrations of said agent
12/01/2005CA2565019A1 1,4 o-linked saccharose derivatives for stabilizing antibodies or antibody derivatives
12/01/2005CA2564778A1 Vaccines
12/01/2005CA2564538A1 Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors
12/01/2005CA2564324A1 Spray-dried powders containing at least one 1,4 o-linked saccharose derivative and methods for producing the same
12/01/2005CA2563735A1 Antibodies and molecules derived therefrom that bind to steap-1 proteins
12/01/2005CA2563666A1 Differentially expressed claudin-18 variants in tumors and use thereof
12/01/2005CA2563432A1 Method for augmenting b cell depletion
12/01/2005CA2562990A1 Mucinous glycoprotein (muc-1) vaccine
12/01/2005CA2562904A1 Cancer treatment using viruses and camptothecins
11/2005
11/30/2005EP1600507A1 Cis-element regulating transcription, transcriptional regulatory factor binding specifically thereto and use of the same
11/30/2005EP1600505A1 Escherichia coli phytase
11/30/2005EP1600164A2 Use of a CD28 binding substance for the production of a pharmaceutical composition with dose-dependent efficacy
11/30/2005EP1599729A1 Diagnostics and therapeutics for diseases associated with aryl hydrocarbon receptor (ahr)
11/30/2005EP1599592A1 Infectious flavivirus pseudo-particles containing functional prm and/or e proteins
11/30/2005EP1599581A2 Production of a live vaccine directed against influenza viruses
11/30/2005EP1599572A2 Compositions and methods for cancer immunotherapy
11/30/2005EP1599503A2 Endothelial cell specific antibodies and uses thereof
11/30/2005EP1599502A1 A molecule which binds cd80 and cd86
11/30/2005EP1599501A2 Modulation of the poliovirus receptor function
11/30/2005EP1599495A2 New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
11/30/2005EP1599228A2 Modified antibodies to prostate-specific membrane antigen and uses thereof
11/30/2005EP1599227A2 Methods of immunomodulation in animals
11/30/2005EP1599226A1 A method of diagnosis and treatment
11/30/2005EP1599225A2 Compositions and methods for the generation of protective immune response against malaria
11/30/2005EP1599224A1 Inhibition of tace or amphiregulin for the modulation of egf receptor signal transactivation
11/30/2005EP1599223A2 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
11/30/2005EP1599221A1 Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
11/30/2005EP1599213A2 Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
11/30/2005EP1599188A2 POWDER FORMULATIONS OF RECOMBINANT STAPHYLOCOCCAL, ENTEROTOXIN B (<SB>R</SB>SEB) MADE BY ATMOSPHERIC SPRAY-FREEZE DRYING FOR IMPROVED VACCINATION
11/30/2005EP1599185A1 Dosage form having a saccharide matrix
11/30/2005EP1599170A2 Human lymphocyte vaccine adjuvant
11/30/2005EP1599165A2 The use of gcc ligands
11/30/2005EP1599164A2 Methods for treating, preventing and detecting helicobacter infection
11/30/2005EP1599128A2 Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
11/30/2005EP1301605B1 Nk cells activating receptors and their therapeutic and diagnostic uses
11/30/2005EP1220612B1 Pediculocidal and veterinary compositions
11/30/2005EP1196586B1 Basb111 polypeptide and polynucleotide from moraxella catharrhalis
11/30/2005EP1192268B1 Nucleic acid binding of multi-zinc finger transcription factors
11/30/2005EP1185306B1 Use of viral vectors and charged molecules for gene therapy
11/30/2005EP1176981B1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/30/2005EP1078063B1 Basb029 polynucleotides and polypeptides from neisseria meningitis
11/30/2005EP0936922B1 Polynucleotide vaccine formula for treating horse diseases
11/30/2005EP0891377B1 Inhibitor and stimulator of haematopoietic stem cell proliferation and uses thereof
11/30/2005EP0870828B1 Novel polypeptide originating from hemophilus paragallinarum and process for producing the same
11/30/2005EP0852623B1 Nucleic acid molecules which code for proteins which mediate the adhesion of neisseria cells to human cells
11/30/2005CN1703513A Tuberculosis vaccines including recombinant bcg strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase
11/30/2005CN1703505A A method of treating an autoimmune disease
11/30/2005CN1703428A Peptides modulating caspase activation
11/30/2005CN1703427A Methods and compositions to generate and control the effector profile of T cells by simultaneous loading and activation of selected subsets of antigen presenting cells
11/30/2005CN1703247A Anti-neovasculature preparations for cancer
11/30/2005CN1703243A Pharmaceutical compositions directed to erb-b1 receptors
11/30/2005CN1703242A Pharmaceutical compositions directed to erb-b1 receptors
11/30/2005CN1703241A Hepatitis b virus surface antigen as a mucosal immunostimulator and the resulting formulations
11/30/2005CN1703239A Vaccine composition comprising interleukin-15 (IL-15)
11/30/2005CN1703238A Recombinant intracellular pathogen immunogenic compositions and methods for use
11/30/2005CN1703236A Use of il-2 receptor antibodies to prevent toxicity associated with amphotericin b antimycotic therapy
11/30/2005CN1701814A F1K-1 is a receptor for vascular endothelial growth factor
11/30/2005CN1701788A Avian polynucleotide vaccine formula
11/30/2005CN1229646C Catalytic anti-factor VIII allo-antibodies
11/30/2005CN1229501C Mixture of recombinant vaccinia vectors as poly-envelope protein vaccines for HIV
11/30/2005CN1229391C Antibody of human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin
11/30/2005CN1229385C Composition for stimulating megacaryocyte growth and differentiation and process thereof
11/29/2005US6969609 nucleic acid sequences encoding a combination of B7, ICAM-1 and LFA-3, wherein expression of the nucleic acid sequences occurs in the host cel
11/29/2005US6969602 Production of an immunovariant strain of Eimeria maxima contributes to strain cross-protection with other Eimeria maximas
11/29/2005US6969520 Active immunization against clostridium difficile disease
11/29/2005US6969518 Compositions and methods for the therapy and diagnosis of breast cancer
11/29/2005US6969517 Anticancer agents; genetic engineered fusion protein
11/29/2005US6969516 Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
11/29/2005US6969513 administering a live attenuated bacterial vector vaccine to a patient, wherein the vaccine containing an isolated cell comprising an expression vector, contains a nucleotide sequence encoding a restricted-copy-number origin of replication cassette
11/29/2005US6969508 Buccal aerosol sprays or capsules using polar and non-polar solvent which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect
11/29/2005CA2331599C Replication defective hiv vaccine
11/29/2005CA2146964C Particles having gelatin-aminodextran coatings of and processes for making same
11/29/2005CA2118329C Isolation, characterization, and use of the human .beta. subunit of the high affinity receptor for immunoglobulin e
11/24/2005WO2005112463A2 Method and formulation for transdermal delivery of immunologically active agents
1 ... 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 ... 1823